profit from every $100 of sales.
$0$100
Inogen
$5.75-4.17% today
-17.7% in 1 year
1-year low $5.091-year high $7.35
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Inogen sold, what it kept, and what it did with the cash.
Sales went from $377 million in 2022 to $349 million in 2025, with -$22.7 million of profit last year.
SalesProfit
Inogen vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Inogen | No profit yet | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads Inogen's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 377 | 316 | 336 | 349 | |
| 154 | 127 | 155 | 154 | |
| -33 | -76 | -43 | -30 | |
| -10 | -58 | -22 | -10 | |
| -84 | -102 | -36 | -23 | |
| -3.67 | -4.42 | -1.52 | -0.86 | |
| 40.7% | 40.1% | 46.1% | 44.2% | |
| -8.8% | -24.2% | -12.7% | -8.7% | |
| -22.2% | -32.5% | -10.7% | -6.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 405 | 326 | 296 | 299 |
| Cash | 187 | 125 | 114 | 104 |
| Total debt | 23 | 22 | 19 | 17 |
| Total liabilities | 108 | 121 | 122 | 106 |
| 297 | 205 | 174 | 192 | |
| 23 | 23 | 24 | 27 | |
| -8.1% | -26.7% | -17.4% | -11.4% | |
| -28.2% | -50.0% | -20.6% | -11.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -38 | -3 | 6 | -11 | |
| 21 | 27 | 17 | 10 | |
| -59 | -30 | -11 | -22 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 12 | 7 | 7 | 8 |
Valuation
- –
- –
- –
- 1.0×
- 0.4×
- –
- –
- -14.4%
- -15.2%
- 0.0%
Profitability
- 44.2%
- -8.7%
- -6.5%
- -1.5%
- -13.2%
- -20.5%
- -12.9%
- -8.7%
- -13.8%
- 5.8%
Growth
- −2.6%
- –
- −93.2%
- –
- +4.8%
Financial health
- -9.0×
- 0.09
- 5.9%
- –
- 3.10
- 2.70
- 1.23
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 22%of 958
Bottom 15%of 888
Bottom 12%of 889
Bottom 7%of 987
What analysts expect
- Average price target
- $26.00
- Range
- $26.00 – $26.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.30 | -0.24 | −25.0% |
| Feb 24, 2026 | -0.26 | -0.36 | +27.8% |
| Nov 5, 2025 | -0.20 | -0.22 | +9.1% |
| Aug 7, 2025 | -0.15 | -0.22 | +31.8% |
| May 7, 2025 | -0.25 | -0.52 | +51.9% |
| Feb 25, 2025 | -0.41 | -0.56 | +26.8% |
| Nov 7, 2024 | -0.25 | -0.49 | +49.0% |
| Aug 6, 2024 | -0.24 | -0.55 | +56.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
67Pass
Philip Fisher
34No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
35No pass
Terry Smith
34No pass
Questions about Inogen
Is Inogen a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Inogen AI analysis
What does Inogen do?
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. It is in Medical - Devices.
Does Inogen pay a dividend?
No. Inogen does not pay a dividend at the moment.
Is Inogen stock halal?
No. Inogen does not pass our halal screen: its cash and confirmed interest-bearing investments are 69% of its market value, at or above the 33% limit. How we check
How has Inogen stock done over the past year?
Down 17.7% over the past twelve months, to $5.75. It traded between $5.09 and $7.35 and is 21.8% below its high.
Who are Inogen's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Inogen's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.